<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T02:44:27Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/12411" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/12411</identifier><datestamp>2026-09-24T01:25:25Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Sheffield, Bill</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Jeffrey Weitz, Patricia Liaw</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Roddick, Leigh Ann C.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-06-18T16:59:31Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-06-18T16:59:31Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="created" lang="en_US">2012-08-27</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2012-10</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">opendissertations/7300</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">8336</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">3268601</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/12411</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/9232</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p>The serpin α-1 proteinase inhibitor (API) normally only impacts the coagulation cascade through its ability to inactivate factor XIa. However, the point mutation (Met to Arg) at position 358 results in a potent thrombin inhibitor, API M358R. This mutation also enhances this serpin’s ability to inhibit the anticoagulant protein, activated protein C (APC) and hence this property limits its therapeutic potential. As a result, various modifications to this protein have been engineered in order to enhance its specificity towards thrombin. Previously, the Heparin Cofactor II (HCII) N-terminal tail, HCII 1-75, which binds exosite 1 of thrombin, was tethered to the N-terminus of API M358R, creating HAPI M358R. Although this change did not alter anti-APC activity, it did augment the anti-thrombin activity of API M358R. In addition, further changes in the reactive center loop, the region that interacts with the thrombin active site, resulted in a significant reduction in APC activity while maintaining antithrombotic activity similar to HAPI M358R; this variant was termed HAPI RCL5.&lt;/p> &lt;p>Preliminary experiments were performed with the C-terminal tridecapeptide of Hirudin Variant 3 (HV3) to determine its exosite 1 binding capacity compared to HCII 1-75. Three different variants of this peptide were tested: one with a hexahistidine tag (H&lt;sub>6&lt;/sub>HV3&lt;sub>54-66&lt;/sub>), another that also had a hexa-glycine C-terminal addition (H&lt;sub>6&lt;/sub>HV3&lt;sub>54-66&lt;/sub>G&lt;sub>6&lt;/sub>) and a third without either addition. All were found to bind exosite 1 with a greater affinity than HCII 1-75. Thus, the H&lt;sub>6&lt;/sub>HV3&lt;sub>54-66&lt;/sub>G&lt;sub>6 &lt;/sub>peptide was fused to API M358R and API RCL5 in hopes of creating an inhibitor with heightened specificity compared to HAPI M358R and HAPI RCL5, respectively.&lt;/p> &lt;p>HV3API M358R and HV3API RCL5 were expressed in a bacterial system and purified by nickel-chelate and ion exchange chromatography. Second order rate constants for the inhibition of thrombin and APC by the API variants and fusion proteins were determined. The K&lt;sub>2&lt;/sub> values for α-thrombin inhibition ranged from 186 M&lt;sup>-1&lt;/sup>min&lt;sup>-1&lt;/sup> to 22 M&lt;sup>-1&lt;/sup>min&lt;sup>-1&lt;/sup> with an order of inhibitory potency observed as follows: HAPI M358R > HAPI RCL5 > HV3API M358R > HV3API RCL5>API RCL5 > API M358R.&lt;/p> &lt;p>The ability of recombinant chimeric serpins to bind thrombin exosite 1 in a manner independent of RCL-thrombin active site interactions was also investigated through competitive inhibition of the binding of active site-inhibited thrombin to immobilized HCII 1-75. It was found that the order of exosite 1 binding affinity was HV3API RCL5 > H&lt;sub>6&lt;/sub>HV3&lt;sub>54-66&lt;/sub>G&lt;sub>6&lt;/sub>> HCII 1-75 > HAPI RCL5. Our results indicate that fusing the C-terminal tridecapeptide of HV3 to API variants enhanced their ability to inhibit thrombin, but to a lesser extent than fusing the N-terminal 75 residues of HCII. This finding likely reflects a requirement for the exosite 1-binding motif of the fusion protein to bind exosite 1 in a way that allows for subsequent optimal active site attack on the RCL by the serpin moiety of the fusion protein. In general, this work provides a second novel example of how the activity of a thrombin-inhibitory serpin can be enhanced by fusion to an exosite-1 binding motif.&lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Health Sciences (MSc)</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">blood</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">coagulation</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">anticoagulants</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">serpins</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">hirudin</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Medical Biochemistry</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Medical Molecular Biology</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Other Medicine and Health Sciences</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Medical Biochemistry</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Fusing the C-terminal tridecapeptide of hirudin to α1-proteinase inhibitor M358R accelerates its rate of thrombin inhibition</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>